Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00034086 · ClinicalTrials.gov registry record · NA
Study of Anti-HIV Therapy Intensification
A NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- NA
- Development phase
- 22
- Enrollment target
NCT00034086: Completed NA study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
NCT00034086 is a NA study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 22 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00034086, a NA study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- NA
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to see how the body's immune system changes after replacing and adding new anti-HIV drugs to a patient's current anti-HIV therapy. This study will also see whether adding drugs is safe. Patients who take part in A5136 are also eligible to take part in 2 substudies. The purpose of substudy A5140s is to see how many latently infected cells (cells in which the HIV virus survives) are in the lymph node (small, rounded structures that make disease-fighting cells). Substudy A5155s will be performed to see how many latently infected cells are in the blood before and after replacing and adding anti-HIV drugs. ACTG A5136 is a follow-up study to ACTG 315 and ACTG 375, which were designed to examine the effects of highly active antiretroviral therapy (HAART) in certain HIV-infected patients. Many HIV-infected patients have undergone long-term anti-HIV therapy and have had the virus suppressed. However, most of these patients still have problems with their immune systems. The reason for these problems is unknown. This study may help researchers understand what causes immune system problems in people who have low levels of HIV in their blood.
Interventions
- DRUG Lamivudine
- DRUG Lamivudine/Zidovudine
- DRUG Lopinavir/Ritonavir
- DRUG Tenofovir disoproxil fumarate
- BIOLOGICAL Pneumococcal Vaccine, Polyvalent (23-valent)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Est. Completion | 2006-06 |
| Phase | NA |
What the finished NCT00034086 record still lists
NCT00034086 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 22 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 5 interventions - of which Lamivudine is the first listed.
NCT00034086 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00034086 about?
NCT00034086 is a clinical study titled "Study of Anti-HIV Therapy Intensification". The purpose of this study is to see how the body's immune system changes after replacing and adding new anti-HIV drugs to a patient's current anti-HIV therapy. This study will also see whether adding drugs is safe. Patients who take part in A5136 are also eligible to take part in 2 substudies. The p...
What is the current status of trial NCT00034086?
This trial is currently completed. It is a NA study. The enrollment target is 22 participants. Estimated completion is 2006-06.
What interventions are being tested in trial NCT00034086?
The interventions under investigation include: Lamivudine (DRUG), Lamivudine/Zidovudine (DRUG), Lopinavir/Ritonavir (DRUG), Tenofovir disoproxil fumarate (DRUG), Pneumococcal Vaccine, Polyvalent (23-valent) (BIOLOGICAL).
Who is sponsoring clinical trial NCT00034086?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00034086's enrollment target sits among peer trials
22 1756th of 2000 higher than 239 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02508038 · 22 participants · Phase 1
Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors
- NCT03099356 · 22 participants · Phase 2
Cyclophosphamide and Sirolimus for the Treatment of Metastatic, RAI-refractory, Differentiated Thyroid Cancer
- NCT03676647 · 22 participants
Diagnostic DNA Methylation Signature in Diagnosing Thyroid Cancer After Fine-Needle Aspiration in Patients With Thyroid Nodules
- NCT04569591 · 22 participants · NA
DDAVP for Pituitary Adenoma